Managing Impending Nonsevere Hypoglycemia With Oral Carbohydrates in Type 1 Diabetes: The REVERSIBLE Trial.

Institut de recherches cliniques de Montréal, Montréal, Québec, Canada. Department of Biomedical Sciences, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada. Endocrinology Division, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada. Endocrinology Division, Hôpital Santa-Cabrini, Montréal, Québec, Canada. Endocrinology Division, Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada. Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada. Experimental Medicine Division, Faculty of Medicine, McGill University, Montréal, Québec, Canada. School of Human Nutrition, McGill University, Montréal, Québec, Canada. Department of Nutrition, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada. Montreal Diabetes Research Center, Montréal, Québec, Canada.

Diabetes care. 2024;(3):476-482

Abstract

OBJECTIVE Current guidelines recommend initiating treatment for nonsevere (NS) hypoglycemia with 15 g carbohydrates (CHO) at 15-min intervals when blood glucose (BG) reaches <70 mg/dL (3.9 mmol/L). Despite this recommendation, NS hypoglycemia management remains challenging for individuals living with type 1 diabetes (T1D). We aimed to assess the efficacy of 15 g CHO at higher BG levels. RESEARCH DESIGN AND METHODS A total of 29 individuals with T1D participated in an open-label crossover study. After an inpatient subcutaneous insulin-induced decrease in BG in the fasting state, 16 g CHO was administered orally at a plasma glucose (PG) of <70 (3.9), ≤80 (4.5), or ≤90 mg/dL (5.0 mmol/L). The primary outcome was time spent in hypoglycemia (<70 mg/dL) after initial CHO intake. RESULTS When comparing the <70 (control) with the ≤80 and ≤90 mg/dL treatment groups, 100 vs. 86 (P = 0.1201) vs. 34% (P < 0.0001) of participants reached hypoglycemia, respectively. These hypoglycemic events lasted 26.0 ± 12.6 vs. 17.9 ± 14.7 (P = 0.026) vs. 7.1 ± 11.8 min (P = 0.002), with a PG nadir of 56.57 ± 9.91 vs. 63.60 ± 7.93 (P = 0.008) vs. 73.51 ± 9.37 mg/dL (P = 0.002), respectively. In the control group, 69% of participants required more than one treatment to reach or maintain normoglycemia (≥70 mg/dL), compared with 52% in the ≤80 mg/dL group and 31% in the ≤90 mg/dL group, with no significant rebound hyperglycemia (>180 mg/dL) within the first hour. CONCLUSIONS For some impending NS hypoglycemia episodes, individuals with TID could benefit from CHO intake at a higher BG level.

Methodological quality

Publication Type : Clinical Trial

Metadata